Page last updated: 2024-10-29

ifosfamide and Emesis

ifosfamide has been researched along with Emesis in 55 studies

Research Excerpts

ExcerptRelevanceReference
"Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy."9.27Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018)
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."9.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."9.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1."9.11A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004)
" In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours."9.10Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."9.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
" Further evaluations of this novel ifosfamide-epirubicin schedule are not warranted, even if the HD-IFO regimen could be taken forward specifically for leiomyosarcomas in a phase II trial."9.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"To compare the efficacy and safety of intravenously administered granisetron with those of chlorpromazine plus dexamethosone in the prevention of ifosmamide-induced emesis in children with malignant disease."9.08A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. ( Cedar, E; Hählen, K; Pinkerton, CR; Quintana, E, 1995)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."7.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1."7.67High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."7.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide."7.67The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989)
"Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy."6.68Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997)
"Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy."6.67The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993)
"Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy."5.27Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018)
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."5.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
"Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma."5.14Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010)
"To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1."5.11A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004)
" In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours."5.10Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."5.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
" Further evaluations of this novel ifosfamide-epirubicin schedule are not warranted, even if the HD-IFO regimen could be taken forward specifically for leiomyosarcomas in a phase II trial."5.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"To compare the efficacy and safety of intravenously administered granisetron with those of chlorpromazine plus dexamethosone in the prevention of ifosmamide-induced emesis in children with malignant disease."5.08A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children. ( Cedar, E; Hählen, K; Pinkerton, CR; Quintana, E, 1995)
"To examine the influence of the proposed symptom cluster of fatigue, nausea and vomiting, and sleep disturbances on clinical outcomes defined as behavior changes, depression, and performance status in children and adolescents before and after receiving cisplatin, doxorubicin, or ifosfamide chemotherapy."3.76Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; Krull, K; McCarthy, K; Sambuco, G, 2010)
"The aim of this study was to investigate the severity and time-course of alterations in gastroduodenal and intestinal permeability in relation to nausea/emesis following administration of the highly emetogenic polydrug regimen IFADIC (ifosfamide, Adriamycin, dacarbazine) using a differential lactulose/mannitol absorption (SLM) test."3.71Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). ( Brodowicz, T; Fazeny-Dörner, B; Marosi, C; Muhm, M; Veitl, M; Vogelsang, H; Wenzel, C; Zielinski, C, 2002)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."3.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide."3.67The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."3.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1."3.67High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985)
"To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)."2.74[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. ( Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009)
"A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus."2.68[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. ( Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997)
"Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy."2.68Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997)
" The overall incidence of adverse experiences was significantly lower in the granisetron group (60."2.67The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group. ( , 1993)
"Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin."2.67Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. ( du Bois, A; Karck, U; Madjar, H; Meerpohl, HG; Prömpeler, H; Thomssen, C; Vach, W, 1994)
"Levels of depression were lower and showed little change."2.67A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. ( Bleehen, NM; Girling, DJ; Machin, D; Stephens, RJ, 1993)
"Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy."2.67The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993)
"Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1."2.40[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. ( Asahi, T; Hata, K; Katayama, Y; Kobashi, K; Kobuke, M; Kondo, K; Kumon, H; Maki, Y; Nanba, K; Nasu, Y; Ochi, J; Ohashi, T; Ohmori, H; Ozaki, Y; Saegusa, M; Saika, T; Tanahashi, T; Tsushima, T; Uno, S; Yamashita, Y, 1998)
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide."1.32Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004)
"Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma."1.30[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma]. ( Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Suda, Y; Terashi, K; Yamamoto, K; Yamato, A, 1997)
"Emesis was characterized by expulsion of solid or liquid material."1.29Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. ( Göthert, M; Herold, H; Szelenyi, I, 1994)

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-199014 (25.45)18.7374
1990's20 (36.36)18.2507
2000's16 (29.09)29.6817
2010's5 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bun, S1
Yonemori, K1
Akagi, T1
Noguchi, E1
Shimoi, T1
Shimomura, A1
Yunokawa, M1
Shimizu, C1
Fujiwara, Y1
Makino, Y1
Hayashi, Y1
Tamura, K1
Xiao, Y1
Liu, J1
Liu, YC1
Huang, XE1
Guo, JX1
Wei, W1
Higgins, SC1
Zakashansky, K1
Bovbjerg, DH1
Hagopian, G1
Shiu, JR1
Romanick, M1
Stobart, K1
Coriat, R1
Mir, O1
Camps, S1
Ropert, S1
Billemont, B1
Leconte, M1
Larousserie, F1
Anract, P1
Alexandre, J1
Goldwasser, F1
Shi, YK1
Yang, S1
Han, XH1
Ma, J1
Ren, HY1
Cen, XN1
Zhou, SY1
Wang, C1
Jiang, WQ1
Huang, HQ1
Wang, JM1
Zhu, J1
Chen, H1
Han, MZ1
Huang, H1
Shen, XM1
Liu, P1
He, XH1
Hockenberry, MJ1
Hooke, MC1
Gregurich, M1
McCarthy, K1
Sambuco, G1
Krull, K1
Jordan, K1
Jahn, F1
Jahn, P1
Behlendorf, T1
Stein, A1
Ruessel, J1
Kegel, T1
Schmoll, HJ1
Huang, YH1
Wen, XP1
Hu, L1
Forni, C2
Loro, L2
Mazzei, T2
Beghelli, C2
Biolchini, A2
Tremosini, M2
Triggiani, A1
Bacci, G2
Chua, DT1
Sham, JS1
Au, GK1
Kopp, HG1
Kanz, L1
Hartmann, JT1
Lorent, N1
De Leyn, P1
Lievens, Y1
Verbeken, E1
Nackaerts, K1
Dooms, C1
Van Raemdonck, D1
Anrys, B1
Vansteenkiste, J1
Takenaka, M1
Okamoto, Y1
Ikeda, K1
Hashimoto, R1
Ueda, T1
Kurokawa, N1
Takagi, T1
Uejima, E1
Hartlapp, JH1
Jaeger, N1
Fischer, P1
Weissbach, L1
Costanzi, JJ2
Morgan, LR2
Hokanson, J1
Holoye, PY2
Anderson, T2
Duelge, J2
Hansen, RM2
Ritch, PS2
Harrison, EF1
Hawke, JE1
Hunter, HL1
Plotkin, D1
Tucker, WG1
Worrall, PM1
Higi, M1
Niederle, N1
Bierbaum, W1
Schmidt, CG1
Seeber, S1
Bleehen, NM1
Girling, DJ1
Machin, D1
Stephens, RJ1
Hählen, K1
Quintana, E1
Pinkerton, CR1
Cedar, E1
Szelenyi, I1
Herold, H1
Göthert, M1
du Bois, A2
Vach, W2
Thomssen, C1
Karck, U1
Madjar, H1
Prömpeler, H1
Meerpohl, HG1
Cullen, MH2
Graziano, SL1
Herndon, JE1
Richards, F1
DiFino, S1
Modeas, C1
Duggan, DB1
Green, MR1
Hewitt, M1
McQuade, B1
Stevens, R1
Markman, M1
Kennedy, A1
Webster, K1
Kulp, B1
Peterson, G1
Belinson, J1
Fujiki, T1
Futatsuki, K1
Akazawa, S1
Yamamoto, K1
Kanda, Y1
Yamato, A1
Terashi, K1
Suda, Y1
Siebert, C1
Holy, R1
Ledergerber, M1
Wechsel, U1
Kriesinger-Schroeder, H1
Noda, K1
Hirabayashi, K1
Terashima, Y1
Ozaki, M1
Yakushiji, M1
Hatae, M1
Kanazawa, K1
Pronzato, P1
Vigani, A1
Pensa, F1
Vanoli, M1
Tani, F1
Vaira, F1
Glisson, B1
Lee, JS1
Palmer, J1
Fossella, F1
Shin, DM1
Murphy, WK1
Perez-Soler, R1
Hong, WK1
Pronk, LC1
Schrijvers, D1
Schellens, JH1
de Bruijn, EA1
Planting, AS1
Locci-Tonelli, D1
Groult, V1
Verweij, J1
van Oosterom, AT1
Maki, Y1
Tsushima, T1
Nasu, Y1
Kumon, H1
Ohmori, H1
Tanahashi, T1
Nanba, K1
Ohashi, T1
Kondo, K1
Saika, T1
Asahi, T1
Saegusa, M1
Ozaki, Y1
Yamashita, Y1
Katayama, Y1
Kobuke, M1
Uno, S1
Ochi, J1
Kobashi, K1
Hata, K1
Han, JY1
Kim, HK1
Choi, BG1
Moon, H1
Hong, YS1
Lee, KS1
Dodd, PM1
McCaffrey, JA1
Hilton, S1
Mazumdar, M1
Herr, H1
Kelly, WK1
Icasiano, E1
Boyle, MG1
Bajorin, DF1
Ferrari, S1
Simoni, P1
Strazzari, S1
Puggioli, C1
Thurnher, D1
Kornfehl, J1
Burian, M1
Gedlicka, C1
Selzer, E1
Quint, C1
Neuchrist, C1
Kornek, GV1
Serrone, L1
Zeuli, M1
Gamucci, T1
Nardi, M1
Cognetti, F1
Fulda, S1
Fichtner, I1
Hero, B1
Berthold, F1
Edmonson, JH1
Petersen, IA1
Shives, TC1
Mahoney, MR1
Rock, MG1
Haddock, MG1
Sim, FH1
Maples, WJ1
O'Connor, MI1
Gunderson, LL1
Foo, ML1
Pritchard, DJ1
Buckner, JC1
Stafford, SL1
Fazeny-Dörner, B1
Veitl, M1
Wenzel, C1
Brodowicz, T1
Zielinski, C1
Muhm, M1
Vogelsang, H1
Marosi, C1
Shepherd, FA1
Evans, WK1
Goss, PE1
Latreille, J1
Logan, D1
Maroun, J1
Stewart, D1
Warner, E1
Paul, K1
Scher, CS1
Amar, D1
McDowall, RH1
Barst, SM1
Falkson, G1
Chasen, MR1
Falkson, HC1
Cantwell, BM1
Carmichael, J1
Mannix, KA1
Harris, AL1
Green, JA1
Watkin, SW1
Hammond, P1
Griggs, J1
Challoner, T1
Chetiyawardana, SD1
Joshi, RC1
Woodroffe, CM1
Wiltshaw, E1
Westbury, G1
Harmer, C1
McKinna, A1
Fisher, C1
Pearcey, R1
Calvert, R1
Mehta, A1
Einhorn, LH1
Marti, C1
Kroner, T1
Remagen, W1
Berchtold, W1
Cserhati, M1
Varini, M1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sleep in Pediatric Hematopoietic Stem Cell Transplant Patients[NCT04106089]50 participants (Actual)Interventional2019-11-18Completed
Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287]Phase 3429 participants (Actual)Interventional2017-09-23Completed
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471]Phase 244 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for ifosfamide and Emesis

ArticleYear
[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1998, Volume: 89, Issue:7

    Topics: Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cis

1998

Trials

29 trials available for ifosfamide and Emesis

ArticleYear
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
    Investigational new drugs, 2018, Volume: 36, Issue:1

    Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsych

2018
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin

2014
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S

2010
[A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:8

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Com

2009
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
    Bone marrow transplantation, 2011, Volume: 46, Issue:6

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Co

2011
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:8

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem

2002
Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours.
    Cancer nursing, 2003, Volume: 26, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Com

2003
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
    Head & neck, 2004, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp

2004
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L

2004
[Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].
    Klinische Wochenschrift, 1982, Mar-01, Volume: 60, Issue:5

    Topics: Adult; Alopecia; Anemia; Bleomycin; Ceruletide; Cisplatin; Constipation; Cyclophosphamide; Drug Ther

1982
Use and safety of high-dose ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc

1982
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
    British journal of cancer, 1993, Volume: 68, Issue:6

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carcinoma, Small Cel

1993
A randomized comparison of intravenously administered granisetron versus chlorpromazine plus dexamethasone in the prevention of ifosfamide-induced emesis in children.
    The Journal of pediatrics, 1995, Volume: 126, Issue:2

    Topics: Adolescent; Antiemetics; Chi-Square Distribution; Child; Child, Preschool; Chlorpromazine; Dexametha

1995
Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Female; Hu

1994
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell

1993
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Cancer, 1993, Jul-01, Volume: 72, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat

1993
The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
    Journal of cancer research and clinical oncology, 1993, Volume: 119, Issue:9

    Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug The

1993
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans

1993
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carci

1997
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro

1997
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Cancer, 1998, Jan-15, Volume: 82, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo

1998
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
    British journal of cancer, 1998, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female;

1998
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:12

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun

1998
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic

2000
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2000, Volume: 8, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone

2000
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot

2001
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
    Medical and pediatric oncology, 2001, Volume: 36, Issue:1

    Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi

2001
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Cancer, 2002, Feb-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined

2002

Other Studies

25 other studies available for ifosfamide and Emesis

ArticleYear
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
    Journal of pain and symptom management, 2008, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F

2008
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Ci

2009
Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide.
    Oncology nursing forum, 2010, Volume: 37, Issue:1

    Topics: Adolescent; Adolescent Behavior; Antineoplastic Agents; Attitude to Health; Child; Child Behavior; C

2010
Hypersensitivity pneumonitis associated with the use of trofosfamide.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro

2004
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3

    Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles

2007
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati

1982
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela

1983
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans;

1982
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
    Journal of cancer research and clinical oncology, 1980, Volume: 97, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm

1980
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
    Journal of pharmacological and toxicological methods, 1994, Volume: 32, Issue:2

    Topics: Animals; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin;

1994
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Huma

1996
[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:5

    Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Huma

1997
The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1997, Volume: 5, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisp

1997
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Human

2002
Report on carcinogenesis bioassay of isophosphamide.
    American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6

    Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma

1978
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma

1992
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1992, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum

1992
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
    Investigational new drugs, 1990, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small

1990
Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:5

    Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; H

1989
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:2

    Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M

1989
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun

1989
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre

1986
Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4

    Topics: Female; Half-Life; Humans; Ifosfamide; Uterine Cervical Neoplasms; Vomiting

1988
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn

1986
High-dose ifosfamide in advanced osteosarcoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Alopecia; Bone Marrow; Cyclophosphamide; Humans; Ifosfamide; Nausea; Osteosarcoma; Prospective Studi

1985